Characterization of antibodies in single-chain format against the E7 oncoprotein of the Human papillomavirus type 16 and their improvement by mutagenesis

被引:14
作者
Dona, Maria Gabriella [1 ]
Giorgi, Colomba [1 ]
Accardi, Luisa [1 ]
机构
[1] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Sect Mol Pathogenesis, I-00161 Rome, Italy
关键词
D O I
10.1186/1471-2407-7-25
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Human papillomaviruses (HPV) are the etiological agents of cervical cancer. The viral E7 protein plays a crucial role in viral oncogenesis. Many strategies have been explored to block the E7 oncoprotein activity. The single-chain variable antibody fragments (scFvs) are valuable tools in cancer immunotherapy and can be used as "intracellular antibodies" to knock out specific protein functions. For both in vivo and in vitro employment, the scFv intrinsic solubility and stability are important to achieve long-lasting effects. Here we report the characterization in terms of reactivity, solubility and thermal stability of three anti-HPV16 E7 scFvs. We have also analysed the scFv43 sequence with the aim of improving stability and then activity of the antibody, previously shown to have antiproliferative activity when expressed in HPV16-positive cells. Methods: The three anti-HPV16 E7 scFv 32, 43 51 were selected from the ETH-2 "phage-display" library. Thermal stability was evaluated with ELISA by determining the residual activity of each purified scFv against the recombinant HPV16 E7, after incubation in the presence of human seroalbumine for different time-intervals at different temperatures. Sequence analysis of the scFvs was performed with BLAST and CLUSTALL programs. The scFv43 aminoacid changes were reverted back to the consensus sequence from the immunoglobuline database by site-directed mutagenesis. ScFv solubility was evaluated with Western blotting by determining their relative amounts in the soluble and insoluble fractions of both prokaryotic and eukaryotic systems. Results: ScFv51 was the most thermally stable scFv considered. Sequence analysis of the most reactive scFv43 has evidenced 2 amino acid changes possibly involved in molecule stability, in the VH and VL CDR3 regions respectively. By mutagenesis, two novel scFv43-derived scFvs were obtained, scFv43 M1 and M2. ScFv43 M2 showed to have improved thermal stability and solubility in comparison with the parental scFv43. Conclusion: The characterization of 5 specific anti-HPV16 E7 scFvs shows features important for their activity in vivo. ScFv43 M2 shows higher thermal stability with respect to the parental scFv43, and scFv51 shows high stability and solubility. These properties make the 2 scFvs the best candidates to be tested for anti-E7 activity in vivo.
引用
收藏
页数:14
相关论文
共 33 条
[1]   Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells [J].
Accardi, L ;
Donà, MG ;
Di Bonito, P ;
Giorgi, C .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (04) :564-570
[2]   Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo [J].
Balsitis, SJ ;
Sage, J ;
Duensing, S ;
Münger, K ;
Jacks, T ;
Lambert, PF .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (24) :9094-9103
[3]  
Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
[4]   Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation [J].
Cardinale, A ;
Filesi, I ;
Vetrugno, V ;
Pocchiari, M ;
Sy, MS ;
Biocca, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (01) :685-694
[5]   The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells [J].
Cardinale, A ;
Lener, M ;
Messina, S ;
Cattaneo, A ;
Biocca, S .
FEBS LETTERS, 1998, 439 (03) :197-202
[6]   Structural determinants in the sequences of immunoglobulin variable domain [J].
Chothia, C ;
Gelfand, I ;
Kister, A .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 278 (02) :457-479
[7]   Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment [J].
Cornelison, TL .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (05) :466-473
[8]   Cervical cancer vaccines: Recent advances in HPV research [J].
Eiben, GL ;
Da Silva, DM ;
Fausch, SC ;
Le Poole, IC ;
Nishimura, MI ;
Kast, WM .
VIRAL IMMUNOLOGY, 2003, 16 (02) :111-121
[9]   Biophysical properties of human antibody variable domains [J].
Ewert, S ;
Huber, T ;
Honegger, A ;
Plückthun, A .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 325 (03) :531-553
[10]   Stability improvement of antibodies for extracellular and intracellular applications:: CDR grafting to stable frameworks and structure-based framework engineering [J].
Ewert, S ;
Honegger, A ;
Plückthun, A .
METHODS, 2004, 34 (02) :184-199